Table I.
Clinical characteristics of 457 patients with myelodysplastic syndromes.
| Patients (n) | % | |
|---|---|---|
| Age, years, Median (range) | 52 (14–83) | |
| Male | 277 | 61 |
| WHO subtype | ||
| MDS-SLD | 15 | 3 |
| MDS-RS-SLD | 12 | 3 |
| MDS-MLD | 251 | 55 |
| MDS-RS-MLD | 3 | 0·7 |
| MDS-EB-1 | 70 | 15 |
| MDS-EB-2 | 92 | 20 |
| MDS with isolated 5q- | 6 | 1·3 |
| MDS-U | 8 | 2 |
| Hb, g/l, median (range) | 77 (31–153) | |
| ANC, × 109/l, median (range) | 1·1 8 (0·04–11·19) | |
| PLT, × 109/l, median (range) | 63 (2–1561) | |
| IPSS-R karyotype (Greenberg et al, 2012) | ||
| Very good | 5 | 1 |
| Good | 270 | 59 |
| Median | 113 | 25 |
| Poor | 26 | 6 |
| Very poor | 43 | 9 |
| IPSS-R risk group (Greenberg et al, 2012) | ||
| Very low | 12 | 3 |
| Low | 115 | 25 |
| Intermedia | 152 | 33 |
| High | 92 | 20 |
| Very high | 86 | 19 |
| Nazha model (Nazha et al, 2016) | ||
| Low | 131 | 29 |
| Intermediate-1 | 165 | 36 |
| Intermediate-2 | 117 | 26 |
| High | 44 | 10 |
| Makishima model (Makishima et al, 2017) | ||
| Low | 27 | 6 |
| Intermediate-1 | 263 | 58 |
| Intermediate-2 | 121 | 27 |
| High | 46 | 10 |
ANC, absolute neutrophil count; Hb, haemoglobin; IPSS-R, Revised International Prognostic Scoring System; MDS, myelodysplastic syndrome; MDS-EB-1/2, MDS with excess blasts type 1/2; MDS-MLD, MDS with multilineage dysplasia; MDS-RS-MLD, MDS with ring sideroblasts (MDS-RS) with multilineage dysplasia; MDS-RS-SLD, MDS-RS with single lineage dysplasia; MDS-SLD, MDS with single lineage dysplasia; MDS-U, MDS unclassifiable; PLT, platelet count; WHO, World Health Organization.